With our combined years of extensive experience delivering programmes into preclinical development, we understand the need for robust, pharmacologically sensitive, high-throughput, multi-modal in-vivo and ex-vivo endpoints that can be put into context with drug exposure levels.

We can offer almost any dosing route and preclinical species that you might require along with a broad range of behavioural end points and tissue / fluid collection capabilities.

Examples include:


pkThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.